Immunotherapy Resistance and Therapeutic Strategies in PD-L1 High Expression Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunology
• Biomarkers

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality.
• High programmed death-ligand 1 (PD-L1) expression (≥50%) identifies patients likely to benefit from immune checkpoint inhibitors (ICIs).
• Despite improved survival, 30-40% of PD-L1-high NSCLC patients experience primary or acquired resistance to ICIs.

Purpose of the Study:

• To systematically review the biological and clinical factors driving ICI resistance in PD-L1-high NSCLC.
• To explore emerging therapeutic strategies for overcoming ICI resistance.
• To highlight the importance of biomarker-guided therapies in NSCLC treatment.

Main Methods:

• Comprehensive literature review of studies on ICI resistance mechanisms in NSCLC.
• Analysis of intrinsic tumor adaptations, immune microenvironment changes, and extrinsic immunosuppressive signals.
• Evaluation of novel combinatorial therapies and biomarker-driven approaches.

Main Results:

• Resistance mechanisms are multifactorial, involving tumor-cell-intrinsic changes, immune evasion, and external immunosuppressive factors.
• Emerging strategies focus on overcoming these complex resistance pathways.
• Biomarker-guided therapies show promise in personalizing treatment for NSCLC patients.

Conclusions:

• Understanding the diverse mechanisms of ICI resistance is crucial for improving outcomes in PD-L1-high NSCLC.
• Novel combinatorial and biomarker-guided strategies are essential for overcoming resistance.
• Further research is needed to optimize these approaches for enhanced patient survival.